# Study of Secukinumab With 2 mL Pre-filled Syringes

> **NCT02748863** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 214 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Secukinumab 2 mL form
- **DRUG:** Secukinumab 1 mL form

## Key facts

- **NCT ID:** NCT02748863
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-12
- **Primary completion:** 2017-08-08
- **Final completion:** 2018-06-08
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2019-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02748863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02748863, "Study of Secukinumab With 2 mL Pre-filled Syringes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02748863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*